ClinicalTrials.Veeva

Menu

The Effect of Macronutrients on Satiety and Gut Hormone Responses (Microcapsule)

Imperial College London logo

Imperial College London

Status

Completed

Conditions

Eating Behavior

Treatments

Dietary Supplement: CHO stomach
Dietary Supplement: Protein distal small intestine
Dietary Supplement: Protein stomach
Dietary Supplement: CHO distal small intestine
Dietary Supplement: Fat stomach
Dietary Supplement: Fat distal small intestine

Study type

Interventional

Funder types

Other

Identifiers

NCT03466047
Microcapsule

Details and patient eligibility

About

This study is part of a research theme aiming at elucidating the physiological mechanisms of action of weight loss after gastric bypass surgery. The Roux-en-Y Gastric Bypass procedure induces pronounced and sustained weight loss, but the physiological mechanisms of action are not completely clear. Neither mechanical restriction of food intake nor malabsorption, are the main contributing factors. The enhanced postprandial responses of gut hormones (e.g. GLP-1 and PYY) which increase satiety as well as energy expenditure after surgery suggest a changed physiological set point for appetite and metabolism.

Our hypothesis is that the intake of high quantity of protein in a microcapsule form would be able to reach the distal parts of the intestinal mucosa and stimulate maximum stimulation of the anorectic gut hormones. The higher functions of the brain will respond to these strong neuroendocrine signals by ensuing satiety and fullness.

Full description

Ten healthy volunteers, aged 18 to 65 years will be recruited. Each subject will be studied on six occasions one week apart. On each visit, a baseline serum sample will be drawn from each subject. In a randomized way all subjects will receive the following meals in their successive weekly visits: Option 1 High protein mixed meal in capsules that break down in the stomach, Option 2 High protein mixed meal in capsules that break down in the distal small bowel, Option 3 High fat mixed meal in capsules that break down in the stomach, Option 4 High fat mixed meal in capsules that break down in the distal small bowel, Option 5 High CHD mixed meal in capsules that break down in the stomach, Option 6 High CHD mixed meal in capsules that break down in the distal small bowel. On the same day, all subjects will be offered standard ad libitum meal to measure their food consumption. After 3 hours (i.e. at 12:00) another blood sample will be drawn. All subjects will be asked to rate their appetite on a Visual Analogue Scale (VAS). Upon VAS completion the subjects will be allowed to go home.

Enrollment

8 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 18-65 years
  • Normal fasting glucose
  • Stable body weight for at least last three months
  • BMI < 30 Kg/m2
  • Capacity to consent to participate
  • Independently mobile

Exclusion criteria

  • Patients who meet any of the following criteria will be excluded:
  • Pre-diabetes Diabetes
  • Obesity
  • Smoking
  • Substance abuse
  • Pregnancy
  • Use of medications (except for oral contraceptives)
  • Chronic medical or psychiatric illness
  • Any significant abnormalities detected on physical examination, electrocardiography, or screening blood tests (measurement of complete blood count, electrolytes, fasting glucose, and liver function)

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

8 participants in 6 patient groups

Protein stomach
Experimental group
Description:
Encapsulated protein released in the stomach
Treatment:
Dietary Supplement: Protein stomach
Protein distal small intestine
Experimental group
Description:
Encapsulated protein released in the distal small intestine
Treatment:
Dietary Supplement: Protein distal small intestine
CHO stomach
Experimental group
Description:
Encapsulated CHO released in the stomach
Treatment:
Dietary Supplement: CHO stomach
CHO distal small intestine
Experimental group
Description:
Encapsulated CHO released in the distal small intestine
Treatment:
Dietary Supplement: CHO distal small intestine
Fat stomach
Experimental group
Description:
Encapsulated Fat released in the stomach
Treatment:
Dietary Supplement: Fat stomach
Fat distal small intestine
Experimental group
Description:
Encapsulated Fat released in the distal small intestine
Treatment:
Dietary Supplement: Fat distal small intestine

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems